Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Subscribe To Our Newsletter & Stay Updated
